The legal answer, and a deadline

Telehealth prescribing of testosterone with no prior in-person visit is legal right now, and that window closes on 31 December 2026.

Testosterone is a Schedule III controlled substance, which normally triggers the Ryan Haight in-person examination requirement. The DEA and HHS Fourth Temporary Rule, published 31 December 2025, authorizes remote prescribing of Schedule II to V without any in-person evaluation, effective 1 January through 31 December 2026. The permanent special registration rule was proposed in January 2025 and, as of July 2026, has not been finalised.

Colorado adds no in-person requirement of its own. Telehealth is held to the same standard as in-person care, an online questionnaire alone does not meet that standard, and Schedule II to IV prescriptions must be transmitted electronically.

The hematocrit corner, and the way out of it

This is the question that ends consultations. Testosterone-driven erythrocytosis is normally managed with two levers: phlebotomy, or dose reduction. Phlebotomy has been off the table given HFE C282Y homozygosity and a ferritin of 34. Dose reduction is the thing to be avoided. A careful clinician hears "you are asking me to accept a risk I have no way to manage."

There is a third lever, and it is the single most useful finding in this research. From the UCSF Gender Affirming Health Program masculinizing therapy guideline, which is the most experienced published source on male-range testosterone and its complications:

Changing to a more frequent injection schedule (maintaining the same total amount of testosterone over time) or transdermal preparations may limit the risk of polycythemia.

The same total weekly dose, split into smaller and more frequent injections, lowers the peak without lowering exposure. Bring this to every conversation. The same guideline also says to check a peak level before concluding there is true polycythemia at all.

Two more pieces of useful ammunition

On reference ranges: a woman registered as female in a lab system, running male-range testosterone, will get high-flagged hemoglobin and haematocrit that may be entirely expected when read against the male range. The UCSF guidance says as much explicitly.

On cardiac risk: the UCSF cardiovascular guideline contains no coronary artery disease exclusion, and states that cardiovascular risk appears unchanged among trans men using testosterone compared with non-transgender women. The only absolute contraindication named anywhere in the masculinising guideline is an active sex-hormone-sensitive cancer.

What to brace for

Expect to hear no more than once, and mostly not because of the virilisation.

• The guideline wall. The 2019 Global Consensus Position Statement on Testosterone Therapy for Women limits dosing to the physiologic premenopausal range and names injections specifically as not recommended. This is the document behind every refusal.
• The coronary disease is the real sticking point. A calcium score of 203 at or above the 90th percentile, with 81 per cent of the burden in the LAD, is what stops prescribers. Erythrocytosis during testosterone therapy is an independent risk factor for major adverse cardiac events and venous thromboembolism, so a prescriber is being asked to maintain a known thrombotic driver alongside a significant coronary lesion.
• There is no supporting trial. The 2020 randomised placebo-controlled study of low-dose testosterone augmentation in women with antidepressant-resistant major depression was negative at every visit, and that was at low dose. There is no controlled evidence at all for supraphysiologic testosterone for depression in women. The case rests on a documented personal response, so bring dated symptom records and the SSRI and bupropion history.
• Nobody has a clean diagnosis code for male-range testosterone in a cisgender woman without gender dysphoria. This is the quiet reason behind a lot of refusals.
• The willing clinics are the least equipped, and the best-equipped will decline. That tension does not fully resolve.

The strategy: split the care

Do not look for one clinician who does everything. Look for a prescriber, plus a preventive cardiologist who knows about the testosterone and manages the lipids, the plaque, and the thrombotic risk. Running male-range testosterone with a cardiologist watching is a materially different risk profile from running it alone.

Prescriber candidates

From the existing provider index, not yet evaluated

Four Colorado names surfaced from the 135-entry index already built for MenopausePracticeGrowth, which the web sweeps missed. Nothing has been verified about their dosing philosophy, their position on coronary disease, or their pricing. They are leads, not recommendations.

• Denver Hormone Institute, Kenton Bruice, MD. Denver, Centennial, Aspen. Search results suggest telemedicine for established patients only.
• thriveMD, Denver and Vail.
• Advanced Gyn, Denver.
• Cunningham Clinic, Denver.

What nobody publishes

No Colorado hormone clinic advertises experience with HFE C282Y homozygosity, and none addresses managing testosterone-driven erythrocytosis in a patient who cannot easily be phlebotomised, at altitude. That specific combination is the hardest thing to source in this entire search, and it is probably the argument for having an academic endocrinologist somewhere in the care team rather than relying on an optimization practice alone.

Almost nobody publishes a numeric target range for female testosterone either. Boulder Peak Health is the exception, and only because it states a physiologic-only position. Everywhere else, the optimization versus physiologic question has to be asked on the phone, which is what the script below is for.

Cardiology partner, to pursue in parallel

South Denver Cardiology Prevention Clinic, Littleton, direct line 303-715-2208. They perform calcium scoring in house and measure ApoB, LDL particle number, and Lp(a). Dr Paul Jurgens practises specifically around what to do with a non-zero calcium score, which is exactly the conversation a score of 203 requires. They take insurance, unlike almost everything else on this page.

If lipid management becomes difficult, the CU Anschutz Cardiometabolic and Advanced Lipid Clinic is the tertiary referral option, with PCSK9 therapy and one of the largest lipoprotein apheresis programs in the country.

Ruled out, and why

• Boulder Peak Health, ten minutes away, commits explicitly to physiologic-only dosing and argues against injections by name on its own site. Right location, wrong philosophy.
• EVEXIAS Denver offers pellets exclusively, which removes the ability to titrate.
• National gender-affirming telehealth (Plume, FOLX, TransClinique) all define their patient population as transgender, non-binary, or gender-diverse in their own site language. QueerDoc is not licensed in Colorado. Worth understanding that an informed-consent model means no letter is required for transition care, not that any indication is accepted.
• Boulder Longevity Institute states on its own site that Dr Yurth is not accepting new Program clients, waitlist or Platinum application only. Other BLI providers appear to be open. Notably BLI refuses pellets on titration grounds and is the only hormone clinic in the area with cardiology under the same roof.

First-contact script

The goal is a yes or no before paying a consult fee. Send this to intake, or ask it on a free discovery call. Do not soften it, because softening it costs a consult fee to hear no.

Question three is the one that sorts people. Anyone who has not thought about it will reveal that immediately. And leading with the Mexico sourcing is the right call: framed as wanting to stop, it reads as a patient moving toward safety, which is exactly the patient a harm-reduction-minded clinician wants. Having it surface later is worse.

Suggested order: Elevated Menopause Care first, Identity Hormones second, Defiance Health third but framed as a monitoring partner rather than the prescriber, and South Denver Cardiology in parallel regardless of who ends up writing the script.

A note on iron and phlebotomy

The obvious idea is to supplement iron, raise ferritin, and then use phlebotomy freely as the hematocrit lever. It is worth asking a clinician about rather than assuming, for three reasons.

C282Y homozygotes hyperabsorb iron because of low hepcidin, so supplemental iron in this genotype is not the neutral act it is in other people. A transferrin saturation of 32 per cent is normal rather than deficient, which suggests the issue is modest stores rather than a transport problem. And now that menstruation has stopped, iron will likely accumulate on its own, which is the whole reason hemochromatosis usually presents later in women than in men.

There is a coherent version of the plan, because regular phlebotomy is the standard treatment for hemochromatosis anyway, and it would serve both problems at once. But the sequencing and the monitoring matter, and the earlier note in this file that iron supplementation is contraindicated came from a prior clinical summary rather than from nowhere. Put it to whoever takes the case.